APTINYX INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2023-12-21: Form 8-K; Period of report 2023-12-21; Description 8.01 Other Events; Details 8.01.
- 2023-12-18: Form 8-K; Period of report 2023-12-15; Description 8.01 Other Events; Details 8.01.
- 2023-07-03: Form 8-K; Period of report 2023-06-30; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders; Details 5.02.
- 2023-05-11: Form 8-K; Period of report 2023-05-10; Description 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; Details 3.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2023-12-21 | 8-K | 2023-12-21 | 8.01 Other Events | 8.01 As previously announced, on December 15, 2023, the Board of Directors of Aptinyx Inc. (the “Company”) authorized and approved a liquidating cash distribution of $6,683,373 (the “Liquidating Distribution”), which is equal to $0.0986975 per share of common stock (the “common stock”) of the Company. | tm2333422d1_8k.htm |
| 2023-12-18 | 8-K | 2023-12-15 | 8.01 Other Events | 8.01 As previously announced, on June 30, 2023, at a special meeting of stockholders of Aptinyx Inc. (the “Company”), the Company’s stockholders approved the liquidation and dissolution of the Company and the Plan of Liquidation and Dissolution (the “Plan of Dissolution”), which authorizes the board of directors of the Company to liquidate and dissolve the Company in accordance with the Plan of Dissolution. | tm2333074d1_8k.htm |
| 2023-07-03 | 8-K | 2023-06-30 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 5.07 - Submission of Matters to a Vote of Security Holders. | tm2320404d1_8k.htm |
| 2023-05-11 | 8-K | 2023-05-10 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On May 10, 2023, Aptinyx Inc. (the “Company”) was notified by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that, based upon the Staff’s determination that the Company is a “public shell” as that term is defined in Nasdaq Listing Rule 5101, and the Company’s non-compliance with certain board and committee composition listing requirements, the Company would be delisted at the opening of business on May 19, 2023 unless the Company timely requests a hearing before a Nasdaq Hearings Panel to address the deficiencies and present a plan to regain compliance. | tm2315321d1_8k.htm |
| 2023-05-05 | 8-K | 2023-05-04 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 The disclosure included under Item 8.01 above is incorporated by reference herein. 8.01 On May 4, 2023, after completing a review of the strategic options available to Aptinyx Inc. (the “Company”), the Company’s board of directors (the “Board”) deemed it in the best interests of the Company and its stockholders that the Company be dissolved. | tm2314810d1_8k.htm |
| 2023-04-25 | 8-K | 2023-04-21 | 1.02 Termination of a Material Definitive Agreement | 1.02 On April 21, 2023 Aptinyx, Inc. (the “Company”) completed voluntary prepayment of all outstanding principal, accrued and unpaid interest, fees, costs and expenses, equal to $27.4 million in the aggregate (the “Payoff Amount”), under the Loan and Security Agreement (the “Loan Agreement”), dated as of September 15, 2021 by and among the Company, the several banks and other financial institutions or entities from time to time parties to the Loan Agreement (collectively, the “Lenders”), and K2 HealthVentures LLC, in its capacity as administrative agent and collateral agent for itself and the Lenders. | tm2313669d1_8k.htm |
| 2023-04-18 | 8-K | 2023-04-14 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On April 14, 2023, Gilmore O’Neill notified the Board of Directors of Aptinyx Inc. of his decision to resign from the Board of Aptinyx Inc., and all committees thereof, effective as of the close of business on April 14, 2023. | tm2313123d1_8k.htm |
| 2023-03-30 | 8-K | 2023-03-30 | 2.02 Results of Operations and Financial Condition | 2.02 On March 30, 2023, Aptinyx Inc. issued a press release announcing its financial results for the year ended December 31, 2022. | tm2311035d1_8k.htm |
| 2023-03-01 | 8-K | 2023-02-26 | 2.05 Costs Associated with Exit or Disposal Activities | 2.05 On February 26, 2023, the Board of Directors (the “Board”) of Aptinyx, Inc. (the “Company”) approved a restructuring plan (the “Plan”) to reduce the Company’s operating costs and better align its workforce with the needs of its business. | tm238175d1_8k.htm |
| 2023-02-27 | 8-K | 2023-02-27 | 8.01 Other Events | 8.01 On February 27, 2023, Aptinyx Inc. issued a press release titled “Aptinyx Reports Results from Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson's Disease and Dementia with Lewy Bodies and Provides Pipeline and Corporate Update.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. | tm237943d1_8k.htm |
| 2022-12-08 | 8-K | 2022-12-07 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On December 7, 2022, Aptinyx Inc. (the “Company”) received approval from The Nasdaq Stock Market LLC (“Nasdaq”) to transfer its stock listing from The Nasdaq Global Select Market to The Nasdaq Capital Market, effective with the opening of the market on December 9, 2022. | tm2232290d1_8k.htm |
| 2022-12-01 | 8-K | 2022-11-28 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On November 28, 2022, Patrick Enright notified the Board of Directors of Aptinyx Inc. of his decision to resign from the Board of Aptinyx Inc., and all committees thereof, effective as of the close of business on November 30, 2022. | tm2231691d1_8k.htm |
| 2022-11-08 | 8-K | 2022-11-08 | 2.02 Results of Operations and Financial Condition | 2.02 On November 8, 2022, Aptinyx Inc. issued a press release announcing its financial results for the quarter ended September 30, 2022. | tm2230010d1_8k.htm |
| 2022-08-25 | 8-K | 2022-08-25 | 8.01 Other Events | 8.01 On August 25, 2022, Aptinyx Inc. issued a press release titled “Aptinyx Completes Enrollment in Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson’s Disease and Dementia with Lewy Bodies.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. | tm2224561d1_8k.htm |
| 2022-08-12 | 8-K | 2022-08-12 | 8.01 Other Events | 8.01 On August 12, 2022, Aptinyx Inc. issued a press release titled “Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Fibromyalgia.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. | tm2223304d1_8k.htm |
| 2022-08-04 | 8-K | 2022-08-04 | 2.02 Results of Operations and Financial Condition | 2.02 On August 4, 2022, Aptinyx Inc. issued a press release announcing its financial results for the quarter ended June 30, 2022. | tm2222586d1_8k.htm |
| 2022-06-10 | 8-K | 2022-06-09 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On June 9, 2022, Aptinyx Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”). | tm2218173d1_8k.htm |
| 2022-05-31 | 8-K | 2022-05-26 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 Aptinyx Inc. (the “Company”) held its Annual Meeting of Stockholders on May 26, 2022. | tm2217275d1_8k.htm |
| 2022-05-12 | 8-K | 2022-05-12 | 2.02 Results of Operations and Financial Condition | 2.02 On May 12, 2022, Aptinyx Inc. issued a press release announcing its financial results for the quarter ended March 31, 2022. | tm2215302d1_8k.htm |
| 2022-04-19 | 8-K | 2022-04-14 | 8.01 Other Events | 8.01 Aptinyx Inc. (Nasdaq: APTX) (the “Company”) has temporarily paused the initiation of its Phase 2b study of the 150 mg dose of NYX-783 in patients with post-traumatic stress disorder (“PTSD”). | tm2212983d1_8k.htm |
| 2022-04-07 | 8-K | 2022-04-07 | 8.01 Other Events | 8.01 On April 7, 2022, Aptinyx Inc. issued a press release titled “Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. | tm2212134d1_8k.htm |
| 2022-03-23 | 8-K | 2022-03-23 | 2.02 Results of Operations and Financial Condition | 2.02 On March 23, 2022, Aptinyx Inc., issued a press release announcing its financial results for the quarter and year ended December 31, 2021. | tm2210231d1_8k.htm |
| 2022-02-28 | 8-K | 2022-02-28 | 8.01 Other Events | 8.01 On February 28, 2022, Aptinyx Inc. issued a press release titled “Aptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in Fibromyalgia.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. | tm227854d1_8k.htm |
| 2022-02-09 | 8-K | 2022-02-09 | 7.01 Regulation FD Disclosure | 7.01 On February 9, 2022, Aptinyx Inc. (the “Company”) presented a portfolio review event to provide an update on its clinical development programs. | tm226001d1_8k.htm |
| 2022-01-03 | 8-K | 2021-12-30 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On December 30, 2021, the Board of Directors (the “Board”) of Aptinyx Inc. (the “Company”) unanimously elected Andy Kidd to the Board, effective January 1, 2022. | tm221274d1_8k.htm |
| 2021-11-09 | 8-K | 2021-11-09 | 2.02 Results of Operations and Financial Condition | 2.02 On November 9, 2021, Aptinyx Inc., issued a press release announcing its financial results for the quarter ended September 30, 2021. | tm2132387d1_8k.htm |
| 2021-10-27 | 8-K | 2021-10-27 | 8.01 Other Events | 8.01 On October 27, 2021, Aptinyx Inc. issued a press release titled “Aptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. | tm2130984d1_8k.htm |
| 2021-10-20 | 8-K | 2021-10-19 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 5.02 On October 19, 2021, the Board of Directors (the “Board”) of Aptinyx Inc. (the “Company”) unanimously appointed Dr. Gilmore O’Neill to the Board. 7.01 On October 20, 2021, the Company issued a press release announcing the appointment of Dr. O’Neill to the Board. | tm2130587d1_8k.htm |
| 2021-09-16 | 8-K | 2021-09-15 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 Entry into a Material Definitive Agreement. 2.03 The information regarding the K2HV Loan Agreement set forth under Item 1.01 of this Current Report on Form 8-K is incorporated by reference in this Item 2.03. | tm2127367d2_8k.htm |
| 2021-08-31 | 8-K/A | 2021-05-10 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On May 07, 2021, the Board unanimously appointed Dr. Miller to the Board. | tm2126694d1_8ka.htm |
| 2021-08-10 | 8-K | 2021-08-10 | 2.02 Results of Operations and Financial Condition; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 2.02 On August 10, 2021, Aptinyx Inc., issued a press release announcing its financial results for the quarter ended June 30, 2021. 5.02 In addition, in its press release dated August 10, 2021, Aptinyx Inc. announced that the Board of Directors approved a leadership transition plan. | tm2124667d1_8k.htm |
| 2021-06-15 | 8-K | 2021-06-15 | 8.01 Other Events | 8.01 On June 15, 2021, Aptinyx Inc. (the “Company”) issued a press release announcing an update regarding its NYX-783 development program for the treatment of post-traumatic stress disorder, or PTSD. | tm2119818d1_8k.htm |
| 2021-06-01 | 8-K | 2021-05-27 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 Aptinyx Inc. (the “Company”) held its Annual Meeting of Stockholders on May 27, 2021. | tm2118156d1_8k.htm |
| 2021-05-13 | 8-K | 2021-05-13 | 2.02 Results of Operations and Financial Condition | 2.02 On May 13, 2021, Aptinyx Inc. issued a press release announcing its financial results for the quarter ended March 31, 2021. | tm2116239d1_8k.htm |
| 2021-05-10 | 8-K | 2021-05-10 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 5.02 On May 07, 2021, the Board of Directors (the “Board”) of Aptinyx Inc. (the “Company”) unanimously appointed Dr. Joan Miller to the Board. 7.01 On May 10, 2021, the Company issued a press release announcing the appointment of Dr. Miller to the Board. | tm2115643d1_8k.htm |
| 2021-03-24 | 8-K | 2021-03-24 | 2.02 Results of Operations and Financial Condition | 2.02 On March 24, 2021, Aptinyx Inc. issued a press release announcing its financial results for the quarter and year ended December 31, 2020. | tm2110648d1_8k.htm |
| 2020-12-16 | 8-K | 2020-12-16 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 5.02 On December 16, 2020, Aptinyx Inc. (“Aptinyx” or the “Company”) announced that, effective December 14, 2020, Andy Kidd has been elevated to the role of president and chief operating officer. 7.01 In connection with Mr. Kidd’s appointment as president and chief operating officer, on December 16, 2020, Aptinyx issued a press release titled “Aptinyx Appoints Andy Kidd, M.D., President and Chief Operating Officer.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. | tm2038589d1_8k.htm |
| 2020-11-12 | 8-K | 2020-11-12 | 2.02 Results of Operations and Financial Condition | 2.02 On November 12, 2020, Aptinyx Inc. issued a press release announcing its financial results for the quarter ended September 30, 2020. | tm2035810d1_8k.htm |
| 2020-10-22 | 8-K | 2020-10-22 | 8.01 Other Events | 8.01 On October 21, 2020, Aptinyx Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with SVB Leerink LLC, Piper Sandler & Co. and Cantor Fitzgerald & Co., as representatives of the underwriters named therein (collectively, the “Underwriters”), relating to the public offering (the “Offering”) of 14,000,000 shares of the Company’s common stock, $0.01 par value per share (the “Common Stock”), at a price to the public of $3.00 per share. | tm2033848-4_8k.htm |
| 2020-10-20 | 8-K | 2020-10-20 | 2.02 Results of Operations and Financial Condition | 2.02 On October 20, 2020, Aptinyx Inc. (the “Company”) announced that it estimates that its cash and cash equivalents were approximately $104 million as of September 30, 2020. | tm2033821-3_8k.htm |
| 2020-10-20 | 8-K | 2020-10-20 | 8.01 Other Events | 8.01 On October 19, 2020, Aptinyx Inc. (the “Company”) announced top-line data from the Company’s Phase 2 study of NYX-783 in patients with post-traumatic stress disorder. | tm2033821d2_8k.htm |
| 2020-10-19 | 8-K | 2020-10-19 | 7.01 Regulation FD Disclosure | 7.01 On October 19, 2020, Aptinyx Inc. (the “Company”) issued a press release titled “Aptinyx Reports Positive, Statistically Significant, Top-line Data from Phase 2 Study of NYX-783 in Patients with Post-Traumatic Stress Disorder.” A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. | tm2033821d1_8k.htm |
| 2020-09-28 | 8-K | 2020-09-28 | 8.01 Other Events | 8.01 On September 28, 2020, Aptinyx Inc. issued a press release titled “Aptinyx Recommences Patient Recruitment in Phase 2 Study of NYX-2925 in Patients with Fibromyalgia.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. | tm2031886-1_8k.htm |
| 2020-08-13 | 8-K | 2020-08-13 | 2.02 Results of Operations and Financial Condition | 2.02 On August 13, 2020, Aptinyx Inc. issued a press release announcing its financial results for the quarter ended June 30, 2020. | tm2027378-1_8k.htm |
| 2020-08-05 | 8-K | 2020-08-05 | 7.01 Regulation FD Disclosure | 7.01 On August 5, 2020, Aptinyx Inc. (the “Company”) updated its corporate presentation, which has been posted on its website. | tm2026528d1_8k.htm |
| 2020-05-22 | 8-K | 2020-05-20 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 Aptinyx Inc. (the “Company”) held its Annual Meeting of Stockholders on May 20, 2020. | tm2020655-1_8k.htm |
| 2020-05-14 | 8-K | 2020-05-14 | 2.02 Results of Operations and Financial Condition | 2.02 On May 14, 2020, Aptinyx Inc. issued a press release announcing its financial results for the quarter ended March 31, 2020. | tm2019581d1_8k.htm |
| 2020-04-06 | 8-K | 2020-04-06 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On April 6, 2020, Aptinyx Inc. (“Aptinyx” or the “Company”) announced that, on April 3, 2020, Wilbur H. Gantz III, the current Chairman of the Company’s Board of Directors (the “Board”), notified the Company of his upcoming retirement, effective as of the close of the Company’s 2020 Annual Meeting of Stockholders on May 20, 2020 (the “Annual Meeting”). | tm2015049-1_8k.htm |
| 2020-03-30 | 8-K | 2020-03-30 | 2.02 Results of Operations and Financial Condition | 2.02 On March 30, 2020, Aptinyx Inc. issued a press release announcing its financial results for the quarter and the year ended December 31, 2019. | f8-k.htm |
| 2020-01-13 | 8-K | 2020-01-13 | 8.01 Other Events | 8.01 On January 10, 2020, Aptinyx Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Cowen and Company, LLC, as representative of the underwriters named therein (collectively, the “Underwriters”), relating to the public offering (the “Offering”) of 10,166,666 shares of the Company’s common stock, $0.01 par value per share (the “Common Stock”), at a price to the public of $3.00 per share. | tm1928324-4_8k.htm |
| 2020-01-09 | 8-K | 2020-01-09 | 2.02 Results of Operations and Financial Condition | 2.02 On January 9, 2020, Aptinyx Inc. (the “Company”) announced that it estimates that its cash and cash equivalents were approximately $99 million as of December 31, 2019. | tm1928324-3_8k.htm |
| 2019-12-04 | 8-K/A | 2019-08-28 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On August 28, 2019, the Board unanimously appointed Dr. Rachel E. Sherman to the Board. | cmw152.htm |
| 2019-11-12 | 8-K | 2019-11-12 | 2.02 Results of Operations and Financial Condition | 2.02 On November 12, 2019, Aptinyx Inc. issued a press release announcing its financial results for the quarter ended September 30, 2019. | a19-22589_18k.htm |
| 2019-09-04 | 8-K | 2019-08-28 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 5.02 On August 28, 2019, the Board of Directors (the “Board”) of Aptinyx Inc. (the “Company”) unanimously appointed Dr. Rachel E. Sherman to the Board. 7.01 On September 4, 2019, the Company issued a press release announcing the appointment of Dr. Sherman to the Board. | a19-18221_18k.htm |
| 2019-08-28 | 8-K/A | 2019-05-06 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On May 6, 2019, the Board unanimously appointed Henry O. Gosebruch to the Board. | cmw127.htm |
| 2019-08-12 | 8-K | 2019-08-12 | 2.02 Results of Operations and Financial Condition | 2.02 On August 12, 2019, Aptinyx Inc., issued a press release announcing its financial results for the quarter ended June 30, 2019. | a19-17008_18k.htm |
| 2019-06-10 | 8-K | 2019-06-10 | 8.01 Other Events | 8.01 On June 10, 2019, Aptinyx Inc. issued a press release titled “Aptinyx Reports Positive Top-line Data from Phase 2 Study of NYX-2925 in Patients with Fibromyalgia, Demonstrating Significant Effects on Both Biomarkers and Patient-Reported Pain”. | a19-11277_18k.htm |
| 2019-05-17 | 8-K | 2019-05-15 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 Aptinyx Inc. (the “Company”) held its Annual Meeting of Stockholders on May 15, 2019. | a19-10198_18k.htm |
| 2019-05-14 | 8-K | 2019-05-14 | 2.02 Results of Operations and Financial Condition | 2.02 On May 14, 2019, Aptinyx Inc. issued a press release announcing its financial results for the quarter ended March 31, 2019. | a19-9902_18k.htm |
| 2019-05-07 | 8-K | 2019-05-06 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On May 6, 2019, the Board of Directors (the “Board”) of Aptinyx Inc. (the “Company”) unanimously appointed Henry O. Gosebruch to the Board. | a19-9454_18k.htm |
| 2019-03-29 | 8-K | 2019-03-25 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On March 25, 2019, Liam Ratcliffe, M.D., Ph.D. provided Aptinyx Inc. (the “Company”) with notice of his resignation from the Board of Directors of the Company, effective as of March 31, 2019. | a19-7426_18k.htm |
| 2019-03-21 | 8-K | 2019-03-21 | 2.02 Results of Operations and Financial Condition | 2.02 On March 21, 2019, Aptinyx Inc., issued a press release announcing its financial results for the quarter and the year ended December 31, 2018. | a19-6956_18k.htm |
| 2019-03-13 | 8-K | 2019-03-13 | 7.01 Regulation FD Disclosure | 7.01 Aptinyx Inc. (the “Company”) will present at the Cowen and Company 39th Annual Health Care Conference on March 13, 2019 at 9:20 a.m. | a19-6491_18k.htm |
| 2019-03-11 | 8-K | 2019-03-11 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On March 7, 2019, Aptinyx Inc. (the “Company”) and Torsten Madsen, M.D., Ph.D., its chief medical officer, agreed that Dr. Madsen’s employment with the Company shall terminate by mutual agreement, effective March 15, 2019. | a19-6273_18k.htm |
| 2019-01-23 | 8-K | 2019-01-17 | 8.01 Other Events | 8.01 On December 19, 2018, the Court of Chancery of the State of Delaware issued a decision in Sciabacucchi v. | a19-3181_18k.htm |
| 2019-01-16 | 8-K | 2019-01-16 | 8.01 Other Events | 8.01 On January 16, 2019, Aptinyx Inc. issued a press release titled “Aptinyx Reports Top-line Results from Phase 2 Clinical Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy”. | a19-3004_18k.htm |
| 2018-11-13 | 8-K | 2018-11-13 | 2.02 Results of Operations and Financial Condition | 2.02 On November 13, 2018, Aptinyx Inc., issued a press release announcing its financial results for the quarter ended September 30, 2018. | a18-40054_18k.htm |
| 2018-08-14 | 8-K | 2018-08-14 | 2.02 Results of Operations and Financial Condition | 2.02 On August 14, 2018, Aptinyx Inc., issued a press release announcing its financial results for the quarter ended June 30, 2018. | a18-18685_18k.htm |
| 2018-06-25 | 8-K | 2018-06-20 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 5.03 As previously disclosed in the Registration Statement on Form S-1 (File No. 333-225150) (the “Registration Statement”) of Aptinyx Inc. (the “Company”), on June 25, 2018 and in connection with the consummation of the initial public offering of the Company’s common stock (the “IPO”), the Company filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware. | a18-8920_98k.htm |